Response to Maccio et al., "Multifactorial Pathogenesis of COVID-19-related Coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?"

Response to Maccio et al., "Multifactorial Pathogenesis of COVID-19-related Coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?" J Thromb Haemost. 2020 Aug 28;: Authors: Richardson E, Carlo-Stella C, Jara R, Vlodavsky I, Iacobelli M, Fareed J, Mo C, O'Gorman P, Yanik G, Palomo M, Diaz-Ricart M, Moraleda JM, DEFACOVID Study Group Abstract We read with interest the letter by Maccio et al., which postulates a role for defibrotide (DF) in the treatment of coagulation disorders observed in COVID-19 [1]. Their commentary effectively explores the contribution of macrophages towards the coagulopathy observed in COVID-19, while highlighting the similarities between COVID-19 associated vascular lesions and veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS) and commonly referred to as VOD/SOS. DF has indeed been shown to improve overall survival in patients with severe VOD/SOS [2] and may be beneficial in the treatment of COVID-19, but not exclusively because of the observed similarities to VOD/SOS. PMID: 32860297 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - Category: Hematology Authors: Tags: J Thromb Haemost Source Type: research